BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zellmer C, Sater MRA, Huntley MH, Osman M, Olesen SW, Ramakrishna B. Shiga Toxin–Producing Escherichia coli Transmission via Fecal Microbiota Transplant. Clinical Infectious Diseases 2021;72:e876-80. [DOI: 10.1093/cid/ciaa1486] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Wong MK, Barbulescu P, Coburn B, Reguera-Nuñez E. Therapeutic interventions and mechanisms associated with gut microbiota-mediated modulation of immune checkpoint inhibitor responses. Microbes Infect 2021;23:104804. [PMID: 33652120 DOI: 10.1016/j.micinf.2021.104804] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cruz N, Abernathy GA, Dichosa AEK, Kumar A. The Age of Next-Generation Therapeutic-Microbe Discovery: Exploiting Microbe-Microbe and Host-Microbe Interactions for Disease Prevention. Infect Immun 2022;:e0058921. [PMID: 35384688 DOI: 10.1128/iai.00589-21] [Reference Citation Analysis]
3 Yadav D, Khanna S. Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2. Therap Adv Gastroenterol 2021;14:17562848211009694. [PMID: 33959193 DOI: 10.1177/17562848211009694] [Reference Citation Analysis]
4 Khanna S, Kraft CS. Fecal Microbiota Transplantation: Tales of Caution. Clin Infect Dis 2021;72:e881-2. [PMID: 32991697 DOI: 10.1093/cid/ciaa1492] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Sandhu A, Chopra T. Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls. Therap Adv Gastroenterol 2021;14:17562848211053105. [PMID: 34992678 DOI: 10.1177/17562848211053105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ghani R, Mullish BH, Roberts LA, Davies FJ, Marchesi JR. The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases. Gut Microbes 2022;14:2038856. [PMID: 35230889 DOI: 10.1080/19490976.2022.2038856] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Lee PC, Chang TE, Wang YP, Lee KC, Lin YT, Chiou JJ, Huang CW, Yang UC, Li FY, Huang HC, Wu CY, Huang YH, Hou MC. Alteration of gut microbial composition associated with the therapeutic efficacy of fecal microbiota transplantation in Clostridium difficile infection. J Formos Med Assoc 2021:S0929-6646(21)00498-8. [PMID: 34836663 DOI: 10.1016/j.jfma.2021.11.001] [Reference Citation Analysis]
8 Bloom PP, Donlan J, Torres Soto M, Daidone M, Hohmann E, Chung RT. Fecal microbiota transplant improves cognition in hepatic encephalopathy and its effect varies by donor and recipient. Hepatol Commun 2022. [PMID: 35384391 DOI: 10.1002/hep4.1950] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Khanna S. Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day! J Intern Med 2021;290:294-309. [PMID: 33856727 DOI: 10.1111/joim.13290] [Reference Citation Analysis]
10 Lee SH, Park H, Kang CD, Choi DH, Park SC, Park JM, Nam S, Chae GB, Lee KY, Cho H, Lee SJ. High Dose Intramuscular Vitamin D3 Supplementation Impacts the Gut Microbiota of Patients With Clostridioides Difficile Infection. Front Cell Infect Microbiol 2022;12:904987. [DOI: 10.3389/fcimb.2022.904987] [Reference Citation Analysis]
11 Orenstein R, Dubberke ER, Khanna S, Lee CH, Yoho D, Johnson S, Hecht G, Dupont HL, Gerding DN, Blount KF, Mische S, Harvey A. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07256-y] [Reference Citation Analysis]
12 Cold F, Svensson CK, Petersen AM, Hansen LH, Helms M. Long-Term Safety Following Faecal Microbiota Transplantation as a Treatment for Recurrent Clostridioides difficile Infection Compared with Patients Treated with a Fixed Bacterial Mixture: Results from a Retrospective Cohort Study. Cells 2022;11:435. [DOI: 10.3390/cells11030435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Khoruts A. Can FMT Cause or Prevent CRC? Maybe, But There Is More to Consider. Gastroenterology 2021:S0016-5085(21)03230-3. [PMID: 34224741 DOI: 10.1053/j.gastro.2021.06.074] [Reference Citation Analysis]
14 Smith DR, Temime L, Opatowski L. Microbiome-pathogen interactions drive epidemiological dynamics of antibiotic resistance: A modeling study applied to nosocomial pathogen control. Elife 2021;10:e68764. [PMID: 34517942 DOI: 10.7554/eLife.68764] [Reference Citation Analysis]
15 Sung JJY, Wong SH. What is unknown in using microbiota as a therapeutic? J Gastroenterol Hepatol 2021. [PMID: 34668228 DOI: 10.1111/jgh.15716] [Reference Citation Analysis]
16 Kao D, Wong K, Franz R, Cochrane K, Sherriff K, Chui L, Lloyd C, Roach B, Bai AD, Petrof EO, Allen-Vercoe E. The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial. Lancet Gastroenterol Hepatol 2021;6:282-91. [PMID: 33631102 DOI: 10.1016/S2468-1253(21)00007-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Gupta S, Mullish BH, Allegretti JR. Fecal Microbiota Transplantation: The Evolving Risk Landscape. Am J Gastroenterol 2021;116:647-56. [PMID: 33982930 DOI: 10.14309/ajg.0000000000001075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]